ProQR's RNA Editing Breakthrough: A New Dawn for Liver Disease Treatment?

LEIDEN, Netherlands & CAMBRIDGE, Mass. – June 25, 2026 – In the intricate world of biotechnology, a 'proof of concept' is the inflection point where a bold scientific idea begins its transformation into a tangible medical reality. ProQR Therapeutics has just crossed that threshold. The company announced positive early-stage clinical data for its investigational therapy, AX-0810, marking the first time its proprietary Axiomer™ RNA editing platform has been validated in humans. This milestone is not just a win for ProQR; it’s a significant development for the entire field of genetic medicine and offers a new glimmer of hope for patients with devastating liver diseases.

Decoding the Data: A Precise Molecular Intervention

The news centers on a Phase 1 study of AX-0810 in healthy volunteers. The drug is designed to treat cholestatic liver diseases, a group of conditions where bile flow is impaired, leading to a toxic buildup of bile acids in the liver. ProQR’s data showed that AX-0810 successfully engaged its intended target, a liver protein called NTCP, which is responsible for clearing bile acids from the blood.

Participants receiving the therapy showed a dose-dependent increase in serum bile acids—up to an 8-fold change at the highest evaluated dose. This figure is crucial, as it far exceeds the 2-fold change the company had predefined as a meaningful sign of drug activity. In essence, the drug appears to be successfully preventing the liver from absorbing these toxic acids, allowing them to be managed and excreted by the body through other means. The therapy also demonstrated a favorable safety profile with no serious adverse events and a half-life of eight weeks, suggesting an infrequent dosing schedule could be possible.

“The concordant responses across all three predefined biomarkers provide compelling clinical target engagement evidence that AX-0810 is modulating NTCP biology in humans as intended,” said Cristina Lopez Lopez, MD, PhD, Chief Medical Officer of ProQR. “These findings support the expected pharmacology of NTCP modulation and were accompanied by a favorable safety and tolerability profile.”

The Axiomer Platform: Rewriting the Code, Not the Blueprint

To appreciate the significance of this milestone, one must look beyond the specific drug to the underlying technology. AX-0810 is the first clinical candidate from ProQR’s Axiomer™ platform, a novel form of RNA editing. Unlike gene-editing technologies like CRISPR that make permanent changes to a cell's DNA, RNA editing is a more transient process. It works on the messenger RNA (mRNA)—the temporary 'instructions' that cells use to build proteins.

ProQR’s approach harnesses a naturally occurring enzyme in our cells called ADAR (Adenosine Deaminase Acting on RNA). The company’s drugs, called Editing Oligonucleotides (EONs), are small, synthetic pieces of RNA that act like a guide. They find the specific target RNA within a cell and create a structure that attracts the ADAR enzyme, which then makes a single, precise letter change in the RNA code. This edit can correct a genetic defect or, in the case of AX-0810, modulate a protein's function to achieve a therapeutic effect.

By leveraging the body's own machinery and avoiding permanent genomic alterations, this approach aims to sidestep some of the long-term safety concerns associated with DNA editing. The validation of this mechanism in a human clinical trial de-risks not only the liver disease program but ProQR’s entire pipeline, which includes candidates for rare genetic disorders like Hurler Syndrome.

A Lifeline for Biliary Atresia

The most immediate impact of this news could be felt by the community surrounding biliary atresia (BA), a rare and devastating pediatric liver disease. In infants with BA, the bile ducts are blocked or absent, leading to rapid liver damage. It is the leading cause of pediatric liver transplants, and without intervention, it is fatal. Current treatment involves a major surgery called the Kasai procedure, but even with surgery, up to 80% of patients will eventually require a liver transplant.

ProQR has designated biliary atresia as the first target indication for its NTCP program. A therapy like AX-0810, which could reduce the toxic bile acid load and potentially slow or halt liver damage, would be a game-changer. It represents a shift from supportive care to a potentially disease-modifying treatment that could prolong the life of a child’s native liver and delay or even prevent the need for a transplant.

“The AX-0810 data represent an important milestone both for the NTCP program and for the Axiomer RNA editing platform,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “The human target engagement data... strengthen our confidence in the potential of the NTCP franchise to address significant unmet need in biliary atresia.”

The Path Forward: From Validation to Application

While this early data is promising, the road ahead is long. ProQR is already advancing a next-generation candidate, AX-0811, which preclinical models suggest could be even more potent and longer-lasting. The company plans to file for a clinical trial with AX-0811 this year and is preparing for an investigator-initiated trial in pediatric BA patients in China, with initial data expected in the first half of 2027. These studies will be critical in determining if the encouraging biomarker data from healthy adults translates into real clinical benefit for patients.

The announcement places ProQR at the forefront of the ADAR-editing space, a competitive arena with other players like Korro Bio and ADARx Pharmaceuticals also vying to bring RNA-editing therapies to the clinic. But with human proof-of-concept now in hand, ProQR has gained a significant head start. For a world grappling with complex diseases, this successful test of a new therapeutic system is a powerful reminder of how a deep understanding of human biology, combined with innovative engineering, can open entirely new pathways to healing.